Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

By T. Hida, H. Nokihara, M. Kondo, Y. H. Kim, K. Azuma, T. Seto, Y. Takiguchi, M. Nishio, H. Yoshioka, F. Imamura and 13 more. The Lancet, 2017

816 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d1b04eb7e8070317e795fa673e2c3fcf5c95183b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017, neutral): “AST increased 37 (25) 16 (11) 21 (14) 8 (5)”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “) in ALK TKI-naive ALK-rearranged advanced NSCLC Japanese patients (J-ALEX trial), demonstrating the superiority of alectinib as an initial targeted treatment [202].”